Express Scripts (ESRX) investors need to consider some of the risks in buying shares of the company. In this video, Fool Jim Mueller outlines three risks to the company's future health. Acquisitions, for example, may be more difficult to come by as Express Scripts could be viewed as having a monopoly on the pharmacy management business. Will the economy discourage new customers? Will synergies be achieved with its acquisitions? Investors need to think about these matters before jumping in.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
3 Reasons to Sell Express Scripts?
Is it time to get out of Express Scripts?
About the Author
Jim learned how businesses are run while putting his Ph.D. in biochemistry to use at a small biotech company. He changed careers to work at the Fool, where he's improved his investing process and developed an appreciation for the long-term view.
Austin Smith and Jim Mueller have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Express Scripts. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned


*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.